NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
The Lipid and Cardiovascular Disease Specialist and the Use of Basic Statistics: Reader Beware
Medical literature is replete with the use of more complex statistics these days, and many of our practice guidelines require more and more rigorously conducted…
Eicosapentaenoic Acid: Pleiotrope Extraordinaire?
The word “pleiotropy” is derived from the Greek word pleon, which means “more,” and tropos, which means “way” and refers to when a gene produces…
Targeting Atherogenic Cholesterol Goals for Patients that Meet the Criteria of ‘Extreme’ ASCVD Risk
The Very High ASCVD Risk Category Atherosclerotic cardiovascular disease (ASCVD) risk assessment has long been simplified to only several major risk factors and only a…
Case Study: Statin Use in the Elderly: An Age-Old Question
Many physicians are faced with a growing elderly population in their practice and the resulting therapeutic dilemmas. A 10- year CVD risk calculation cannot be…
My Statin or My Sarcolemma? Could Vitamin D Provide Some Answers for Improved Statin Compliance?
Data from the Cholesterol and Recurrent Events (CARE), Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), and Scandinavian Simvastatin Survival Study (4S) trials have shown…
Age-Related Pharmacokinetic Changes and the Impact on Statin Therapy in Older Patients
While there is evidence for atherosclerotic cardiovascular risk reduction with statins in both primary and secondary prevention in older patients, there is a higher incidence…
From Microbes to Foam Cells
Atherosclerosis is a lipid-driven disorder and the main underlying cause of cardiovascular disease (CVD). Microbiology has long been a critical focal area of medicine in…
The Use of Statins to Reduce Cardiovascular Risk in the Elderly
There is compelling and consistent evidence from clinical outcome trials that reducing the level of LDL-C with statins reduces the risk of having an ASCVD…